Humana (HUM) AI Stock Analysis

Top Page

Humana

(XETRA:HUM)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

CenterWell capital flexibilityThe new joint venture provides additional growth capital for CenterWell while keeping Humana responsible for clinic operations. Removing prior put arrangements should reduce balance-sheet liabilities and lower funding costs, improving financial flexibility for expansion and strategic investment.

Negative Factors

Compressed profitabilityThe sharp decline in net and operating margins shows that revenue growth is currently translating into relatively little earnings. Lower profitability reduces internal reinvestment capacity, weakens returns to shareholders, and leaves less cushion against medical-cost or policy pressures.

Humana (HUM) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 49.77B
Dividend Yield: 0.85%
Average Volume (3M): 22
Price to Earnings (P/E): 38.9
Beta (1Y): 0.13
Revenue Growth: 10.31%
EPS Growth: -24.29%
Country: Germany
Employees: 67,060
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Healthcare Plans

Humana Business Overview & Revenue Model

Company Description

Humana Inc., a prominent health and well-being enterprise, operates across the United States through its various subsidiary companies. Its operational structure is divided into three main segments: Retail, Group and Specialty, and Healthcare Services...

Humana Earnings Call Summary

Earnings Call Date:Jul 28, 2026(Q2-2026)|% Change Since:11.02%|Next Earnings Date:Nov 05, 2026

Earnings Call SentimentPositive

The call conveyed a generally constructive operational and strategic progress narrative: clear cost-reduction execution (120 bps Y/Y improvement in Q2 operating cost ratio and expected ~150 bps full-year), tangible improvement in key Stars-related measures (outperforming historical CAGR on most selected metrics and ~5% better quality improvement rate for BY '29 measures), balance-sheet moves (Gentiva divestiture ~ $900M and $1.5B P-Cap facilities) and a new statewide Medicaid win. However, material risks remain — notably elevated and rising drug trend, dependence on membership mix for margin realization, plan-exit disruption (~600k members), elevated reserves/IBNR, and Stars/ policy uncertainty — which temper the outlook. On balance, the highlights (execution, cost savings, Stars operational progress, capital actions) outweigh the lowlights (policy uncertainty, drug trend, membership disruption), producing a cautiously positive sentiment.

Positive Updates

On-Track to 2028 Margin Goal

Management reiterated they are tracking to expectations for 2026 and expect 2027 MA bids to drive progress toward a sustainable pretax margin of at least 3% in 2028; they expect meaningful margin expansion in 2027 though final results will depend on membership size and composition.

Negative Updates

Stars Outcome Uncertainty and Litigation Risk

While operational improvements are strong, outcomes remain uncertain because CMS thresholds are unknown until final release; management also noted ongoing litigation and policy uncertainty around the MA Stars program which could affect future incentives and competitive positioning.

Company Guidance

Humana guided that 2026 cost trends are expected to be high single‑digit (7–8% all‑in, with drug trend in the double digits and expected to tick modestly higher in 2027), Q2 consolidated operating cost ratio improved 120 basis points year‑over‑year (with a full‑year reduction of ~150 bps expected), and the company remains on track to double individual MA pretax margin in 2026 (excluding the Stars headwind) and to reach a sustainable pretax margin of at least 3% in 2028 with meaningful margin progress expected in 2027; bids incorporate contingency (submitted ~6 months ahead) and assume trends in line with 2026, plan exits are expected to affect ~600,000 members (with recapture similar to 2025 at just over 40% and many exits in plans with ≤3.5 ratings), BY‑28 Stars operational progress outpaced historical CAGR on 11 of 12 selected HEDIS/patient‑safety measures and top‑quartile Stars is defined as Stars revenue PMPM 10% above the peer median, BY‑29 quality improvement remains ~5% ahead year‑over‑year on a per‑member basis, IBNR was flat sequentially after earlier year‑over‑year increases, Humana established $1.5 billion of contingent P‑Cap facilities and announced a ~$900 million Gentiva minority‑interest divestiture expected to close in Q4, and the company won a statewide Illinois Medicaid contract going live January 2027 as the only new entrant among six carriers.

Humana Risk Analysis

Humana disclosed 16 risk factors in its most recent earnings report. Humana reported the most risks in the "Production" category.

Production - Risks related to the company’s ability to manufacture goods and services

Latest Risks Added

0 New Risks

Humana Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:HUM against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CI	72Outperform	$78.80B	12.30	15.24%	2.08%	8.15%	31.47%
ELV	69Neutral	$90.76B	17.89	11.59%	1.64%	3.60%	-4.06%
CNC	64Neutral	$33.89B	23.13	6.78%	―	9.71%	―
UNH	62Neutral	$365.29B	23.23	16.10%	2.23%	3.33%	―
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CVS	48Neutral	$115.43B	23.56	6.43%	2.95%	7.41%	6.51%

* Healthcare Sector Average

Performance Comparison

DE:HUM and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:HUM	Humana	370.00	130.15	54.27%
CNC	Centene	68.45	33.95	98.41%
CI	Cigna	298.23	45.34	17.93%
CVS	CVS Health Corp	90.25	14.15	18.59%
UNH	Unitedhealth Group Inc.	406.97	81.84	25.17%
ELV	Elevance Health, Inc.	420.07	112.99	36.79%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Humana AI Stock Analysis